DiGA Cara Care für Reizdarm - Evaluation of a non-invasive, non-additionally burdensome, prospective, multicentered, two-armed, randomized trial with parallel group design

Organizational Data

DRKS-ID:
DRKS00026631
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2021-10-06
Last update in DRKS:
2024-05-03
Registration type:
Prospective

Acronym/abbreviation of the study

No Entry

URL of the study

https://cara.care/de/

Brief summary in lay language

The digital health application Cara Care für Reizdarm (Cara Care for irritable bowel syndrome) is an app intended for the digital treatment of irritable bowel syndrome (IBS). The app has the goal to reduce the severity of IBS symptoms and improve quality of life (QoL). In 2020, the efficacy of the app was already analysed with the help of standardized medical questionnaires. The planned clinical study has the aim to analyse these effects in more detail. It will be evaluated whether the use of the app Cara Care für Reizdarm can lead to positive care effects for patients with IBS.

Brief summary in scientific language

Cara Care für Reizdarm is an interactive, software-based medical application, which utilizes the most recent findings from gastroenterological medicine, nutritional science, and psychological research to create a personalized digital treatment for IBS. The application of Cara Care für Reizdarm is based on anamnestic and medically validated questionnaires, which collect patient data at the beginning and in regular intervals. These data are incorporated into an algorithm which determines the content provided to the user. This study will analyze if the use of the digital health application (DiGA) Cara Care für Reizdarm has positive care effects for patients with irritable bowel syndrome (IBS). The primary study objective is the confirmation of the superiority of the application of the DiGA Cara Care für Reizdarm (intervention group) compared to the non-application of the DiGA (control group). The superiority will be evaluated by comparing the intervention and the control group with regards to a change in disease-specific symptom severity (measured via IBS-SSS).

Health condition or problem studied

ICD10:
K58.1 - Irritable bowel syndrome with predominant diarrhoea [IBS-D]
ICD10:
K58.2 - Irritable bowel syndrome with predominant constipation [IBS-C]
ICD10:
K58.3 - Irritable bowel syndrome with mixed bowel habits [IBS-M]
ICD10:
K58.8 - Other and unspecified irritable bowel syndrome
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Access to the full version of the App
Arm 2:
Standard of Care and no application of the App Cara Care für Reizdarm or an alternative App

Endpoints

Primary outcome:
The alteration of disease severity - measured by Irritable Bowel Syndrome - Severity Scoring System (IBS-SSS) in the intervention and control groups will be used as the primary endpoint. Quality of life (measured using IBS-QOL). Work and activity impairment (measured using WPAI-IBS) Health literacy (measured using HLS-EU-Q16). Data was collected using standardized health questionnaires.
Secondary outcome:
Perception of anxiety (measured using GAD-7) Perception of depressiveness (measured using PHQ-9) Data was collected using standardized health questionnaires.

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Multicenter study
Recruitment location(s):
  • Medical center Medizinische Hochschule Brandenburg Brandenburg
  • University medical center Charité Universitätsmedizin Berlin
  • Doctor's practice Berlin
  • Other Klinische Forschung Berlin Mitte GmbH Berlin

Recruitment period and number of participants

Planned study start date:
2021-10-28
Actual study start date:
2021-12-15
Planned study completion date:
2024-01-29
Actual Study Completion Date:
2024-02-27
Target Sample Size:
374
Final Sample Size:
378

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
70 Years
Additional Inclusion Criteria:
● Medically confirmed diagnosis according to ICD-10-GM (K58.- i.e.: K58.1, K58.2, K58.3, K58.8). ● signed Informed Consent Form. ● Access to tablet/smartphone with internet access. ● Willingness to use DiGA Cara Care for IBS on a regular, independent basis for at least 12 weeks. ● Willingness to answer questions at four time points over a minimum of 12 weeks.

Exclusion Criteria

•Age < 18 years as well as > 70 years •Pregnancy •Addiction or other illness, including mental illness (e.g., dementia, i.e., F00-F07), which may not enable patients to assess the nature and scope as well as possible consequences of participation in the study •Insufficient knowledge of the German language which is necessary to participate in the trial •Past use of DiGA Cara Care for irritable bowel syndrome for a period of more than 2 weeks

Addresses

Primary Sponsor

Address:
HiDoc Technologies GmbH
Dr. André Sommer
Hohe Bleichen 22
20354 Hamburg
Germany
Telephone:
030 30809546
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
No

Contact for Scientific Queries

Address:
Städtisches Klinikum Brandenburg GmbHHochschulklinikum der MHBZentrum für Innere Medizin II
Univ.-Prof. Dr. med. Stefan Lüth
Hochstraße 29
14770 Brandenburg an der Havel
Germany
Telephone:
03381411600
Fax:
03381411609
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.klinikum-brandenburg.de/fachbereiche/zentrum-fuer-innere-medizin-ii

Contact for Public Queries

Address:
Städtisches Klinikum Brandenburg GmbHHochschulklinikum der MHBZentrum für Innere Medizin II
Univ.-Prof. Dr. med. Stefan Lüth
Hochstraße 29
14770 Brandenburg an der Havel
Germany
Telephone:
03381411600
Fax:
03381411609
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.klinikum-brandenburg.de/fachbereiche/zentrum-fuer-innere-medizin-ii

Principal Investigator

Address:
Städtisches Klinikum Brandenburg GmbHHochschulklinikum der MHBZentrum für Innere Medizin II
Univ.-Prof. Dr. med. Stefan Lüth
Hochstraße 29
14770 Brandenburg an der Havel
Germany
Telephone:
03381411600
Fax:
03381411609
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.klinikum-brandenburg.de/fachbereiche/zentrum-fuer-innere-medizin-ii

Sources of Monetary or Material Support

Commercial (pharmaceutical industry, medical engineering industry, etc.)

Address:
HiDoc Technologies GmbH
Hohe Bleichen 22
20354 Hamburg
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission der Medizinischen Hochschule Brandenburg
Fehrbelliner Straße 38
16816 Neuruppin
Germany
Telephone:
03391 39-14663
Fax:
03391 39-14669
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.mhb-fontane.de/ethikkommission.html

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2021-08-03
Ethics committee number:
E-01-20210803
Vote of the Ethics Committee:
Approved
Date of the vote:
2021-09-30

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
DE-MF-000007353

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
Yes
IPD Sharing Plan:
The aim of the study is to obtain a permanent inclusion into the DIGA register of the BfArM, therefore the data will be forwarded to the BfArM. At the end of the study, the anonymized results might be made available in a summary of the clinical study report and publications.

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry